PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for January 18, 2008 Subscribe to this News Feed    
 

Innovative Cold Sore Treatment Device Virulite Comes to US

Successful in the UK, Device Reduces Healing Time by up to 50%

COSTA MESA, Calif. (Business Wire EON/PRWEB ) January 18, 2008 -- Virulite, LLC, a medical device manufacturer dedicated to developing the market for an innovative new treatment for cold sores, today announced that it has retained Compass Point Capital, Inc. and Murphy Business and Financial Corporation as its mergers and acquisitions advisors.

Virulite, LLC has validated the US market for the Virulite device by successfully completing clinical trials and is presently in the process of obtaining FDA clearance. The Virulite product is successful in the UK and is both approved by the British National Health Service and CE marked.

The Virulite product, (patents granted and pending), is a portable, hand held device that uses an invisible, non-thermal band of near-infrared light. Virulite was developed in the UK after ten years of research and development, and has been medically proven in independent clinical trials to reduce the healing time of cold cores by up to one half.

The company completed a US market test of the product through Walgreens online distribution channel, where Virulite outsold all competing cold sore remedies, including the current market leader, the topical cream Abreva by GlaxoSmithKline (GSK). In addition, Virulite received numerous customer testimonials from users who experienced astonishing results. Virulite, LLC recognizes the product requires a home with an established pharmaceutical, health product or medical device company in order to effectively penetrate the estimated $4 billion cold sore remedy market, and is actively seeking suitors.

About Virulite, LLC

Virulite LLC is focused on developing consumer markets using the Virulite 1072 nanometer technology. While the cold sore treatment is proven, the technology also has shown anecdotal success in treating genital herpes, bacterial infections and warts (clinical trials are underway for the latter two). For more information, visit http://www.virulite.com

About Compass Point Capital, Inc. and Murphy Business and Financial Corporation

Compass Point is a leading west coast mergers and acquisition firm specializing in middle market companies and will be working with Murphy Business, one of the largest business sales organizations with offices nationwide. For more information, visit http://www.compasspointcapital.com and http://www.murphybusiness.com

See the original story at: http://eon.businesswire.com/releases/virulite/device/prweb638501.htm

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SGFsZi1Db3VwLUNyYXMtSG9yci1Mb3ZlLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareThis
CONTACT INFORMATION

Murphy Business and Finance
Randy Malmud, 310-285-1760
Fax: 310-694-9079
R.malmud@murphybusiness.com

ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Close Move